1-(3-氨基-5-溴-2-羟基苯基)乙酮 | 70977-85-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(3-氨基-5-溴-2-羟基苯基)乙酮
• 英文名称: 1-(2-hydroxy-3-amino-5-bromophenyl)ethan-1-one
• 英文别名: 3-Amino-5-brom-2-hydroxy-acetophenon；3-amino-5-bromo-2-hydroxyacetophenone；1-(3-amino-5-bromo-2-hydroxyphenyl)ethanone
• CAS: 70977-85-4
• 化学式: C₈H₈BrNO₂
• mdl: MFCD12196330
• 分子量: 230.061
• InChiKey: AVBHUFWNYCSYBN-UHFFFAOYSA-N

物化性质

• 熔点：
  99–102°C
• 沸点：
  344.1±42.0 °C(Predicted)
• 密度：
  1.668±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922509090

反应信息

• 作为反应物：
  描述：

  1-(3-氨基-5-溴-2-羟基苯基)乙酮 在 palladium on activated charcoal 、 氢气 作用下， 以 乙醇 为溶剂， 反应 8.0h， 以91%的产率得到3-氨基-2-羟基苯乙酮
  参考文献：
  名称：

  一种制备普仑司特关键中间体3-氨基-2-羟基 苯乙酮的制备方法

  摘要：

  本发明提供了一种制备普仑司特关键中间体3‑氨基‑2‑羟基苯乙酮的制备方法，本发明以2‑氨基苯酚为起始原料，通过以2‑氨基苯酚与乙酸酐，在水中反应合成2‑乙酰胺基苯酚，然后将2‑乙酰氨基苯酚与NBS在室温下制得2‑乙酰氨基‑4‑溴苯酚，再通过Hoesch反应制备2‑羟基‑3‑氨基‑5‑溴苯乙酮，最后将2‑羟基‑3‑氨基‑5‑溴苯乙酮溶于乙醇中，加入Pd/C催化加氢脱溴制得3‑氨基‑2‑羟基苯乙酮，本发明所采用的原料价格便宜易得，原料选择多样化，生产工艺易实现，易管控，所得最终产品纯度高，无危险工艺，设备简单，合成路线新颖，合成路线短，提升产能，降低生产加工成本。

  公开号：

  CN107098822B
• 作为产物：
  描述：

  邻乙酰氨基酚 在 盐酸 、 N-溴代丁二酰亚胺(NBS) 、 zinc(II) chloride 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 23.0h， 生成 1-(3-氨基-5-溴-2-羟基苯基)乙酮
  参考文献：
  名称：

  一种制备普仑司特关键中间体3-氨基-2-羟基 苯乙酮的制备方法

  摘要：

  本发明提供了一种制备普仑司特关键中间体3‑氨基‑2‑羟基苯乙酮的制备方法，本发明以2‑氨基苯酚为起始原料，通过以2‑氨基苯酚与乙酸酐，在水中反应合成2‑乙酰胺基苯酚，然后将2‑乙酰氨基苯酚与NBS在室温下制得2‑乙酰氨基‑4‑溴苯酚，再通过Hoesch反应制备2‑羟基‑3‑氨基‑5‑溴苯乙酮，最后将2‑羟基‑3‑氨基‑5‑溴苯乙酮溶于乙醇中，加入Pd/C催化加氢脱溴制得3‑氨基‑2‑羟基苯乙酮，本发明所采用的原料价格便宜易得，原料选择多样化，生产工艺易实现，易管控，所得最终产品纯度高，无危险工艺，设备简单，合成路线新颖，合成路线短，提升产能，降低生产加工成本。

  公开号：

  CN107098822B

文献信息

• [EN] SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE<br/>[FR] COMPOSÉS D'HYDROXYÉTHYLAMINE SUBSTITUÉE EN TANT QUE MODULATEURS DE BÊTA-SÉCRÉTASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2009064418A1

  公开（公告）日：2009-05-22

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula (I) I wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, X and Z are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions. The invention also comprises further embodiments of Formula II, intermediates and processes useful for the preparation of compounds of Formulas I and II.

  本发明涵盖了一类新化合物，用于调节Beta-分泌酶酶活性，治疗由Beta-分泌酶介导的疾病，包括阿尔茨海默病（AD）及相关疾病。在一种实施方案中，这些化合物具有一般的化学式（I），其中R1、R2、R3、R4、R5、A1、A2、A3、A4、X和Z在此定义。该发明还包括将这些化合物用于制备药物组合物，用于治疗与beta-分泌酶蛋白活性相关的疾病和症状，如阿尔茨海默病（AD）、认知缺陷和损伤、精神分裂症和其他类似的中枢神经系统疾病。该发明还包括进一步的化学式II实施方案，以及用于制备化合物I和II的中间体和工艺。
• Substituted Pyrano [2,3-b] Pyridinamine compounds as beta-secretase modulators and methods of use
  申请人：Graceffa Russell

  公开号：US20100120774A1

  公开（公告）日：2010-05-13

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , X and Z are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions. The invention also comprises further embodiments of Formula II, intermediates and processes useful for the preparation of compounds of Formulas I and II.

  本发明包括一类新化合物，用于调节Beta-分泌酶酶活性，治疗由Beta-分泌酶介导的疾病，包括阿尔茨海默病（AD）及相关疾病。在一个实施例中，这些化合物具有一般的化学式I，其中R1、R2、R3、R4、R5、A1、A2、A3、A4、X和Z在此处被定义。该发明还包括将这些化合物用于治疗与beta-分泌酶蛋白活性相关的疾病和情况的药物组合物。这些疾病包括阿尔茨海默病（AD）、认知缺陷和损伤、精神分裂症和其他类似的中枢神经系统疾病。该发明还包括化学式II的进一步实施例，以及有用于制备化学式I和II化合物的中间体和工艺。
• Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
  申请人：Zhong Wenge

  公开号：US20090036478A1

  公开（公告）日：2009-02-05

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein R 1a , R 1b , R 1c , B, W, R 3 , R 4 and R 5 are defined herein. In another embodiment, the invention provides compounds of general Formula II wherein A 1 , A 2 , A 3 , A 4 , R 1a , R 1b , R 1c , R 2 , R 4 , R 5 , W, X and Z are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions. The invention also comprises further embodiments of Formula II, intermediates and processes useful for the preparation of compounds of Formulas I and II.

  本发明涉及一类新化合物，适用于调节Beta-分泌酶酶活性和治疗Beta-分泌酶介导的疾病，包括阿尔茨海默病（AD）和相关疾病。在一种实施例中，该化合物具有一般的I式，其中R1a、R1b、R1c、B、W、R3、R4和R5在此定义。在另一种实施例中，本发明提供了一般式II的化合物，其中A1、A2、A3、A4、R1a、R1b、R1c、R2、R4、R5、W、X和Z在此定义。本发明还包括这些化合物在制药组合物中的使用，用于治疗与Beta-分泌酶蛋白活性相关的疾病和症状。这些疾病包括阿尔茨海默病（AD）、认知缺陷和损伤、精神分裂症和其他类似的中枢神经系统疾病。本发明还包括进一步的II式实施例、中间体和制备I式和II式化合物的有用工艺。
• Substituted spirocyclic chromanamine compounds as Beta-Secretase modulators and methods of use
  申请人：Amgen Inc.

  公开号：US07951838B2

  公开（公告）日：2011-05-31

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, X and Z are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions. The invention also comprises further embodiments of Formula II, intermediates and processes useful for the preparation of compounds of Formulas I and II.

  本发明涉及一种新的化合物类别，用于调节β-秘鲁酶酶活性并用于治疗β-秘鲁酶介导的疾病，包括阿尔茨海默病（AD）和相关疾病。在一种实施方案中，所述化合物具有一般式I，其中R1、R2、R3、R4、R5、A1、A2、A3、A4、X和Z在此定义。本发明还包括这些化合物在制药组合物中的使用，用于治疗与β-秘鲁酶蛋白活性相关的疾病和状况，例如阿尔茨海默病（AD）、认知缺陷和损伤、精神分裂症和其他类似的中枢神经系统疾病。本发明还包括公式II的进一步实施方案、中间体和用于制备公式I和II化合物的有用过程。
• Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
  申请人：Amgen Inc.

  公开号：US07803809B2

  公开（公告）日：2010-09-28

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, X and Z are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions. The invention also comprises further embodiments of Formula II, intermediates and processes useful for the preparation of compounds of Formulas I and II.

  本发明涉及一类新型化合物，可用于调节Beta-分泌酶酶活性和治疗Beta-分泌酶介导的疾病，包括阿尔茨海默病（AD）和相关疾病。在一种实施例中，所述化合物具有一般式I，其中R1、R2、R3、R4、R5、A1、A2、A3、A4、X和Z在此定义。本发明还包括将这些化合物用于制备药物组合物，用于治疗与beta-分泌酶蛋白活性相关的疾病和症状，例如阿尔茨海默病（AD）、认知缺陷和损伤、精神分裂症和其他类似的中枢神经系统疾病。本发明还包括进一步的II式实施例、中间体和制备I式和II式化合物的有用过程。